Duration of GnRH-Analogue Downregulation and Pregnancy Rates
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to assess whether the probability of pregnancy is dependent on the duration of GnRH agonist downregulation in IVF cycles.
| Condition | Intervention | Phase |
|---|---|---|
|
Infertility |
Drug: GnRH agonists |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Effect of the Duration of GnRH-Analogue Downregulation on Pregnancy Rates in IVF |
- pregnancy rate
| Estimated Enrollment: | 300 |
| Study Start Date: | May 2006 |
| Estimated Study Completion Date: | January 2007 |
GnRH agonists have been used extensively in assisted reproduction technologies for inhibition of gonadotropin secretion from the pituitary prior to initiation of ovarian stimulation. Administration of GnRH agonists results in the prevention of spontaneous LH surges, which lead to luteinization of the developing follicles, initiation of final oocyte maturation and a decrease in pregnancy rates.
GnRH agonists are usually administered according to two protocols: the short and long protocol.In the long protocol, downregulation with GnRH agonists is initiated either in the middle of the secretory phase, or at the beginning of the follicular phase. Stimulation of the ovaries with gonadotropins is initiated when downregulation is confirmed.
Administration of gonadotropins is usually started during the second or third week of treatment with GnRH agonists.The possibility of earlier initiation of the ovarian stimulation, if downregulation is confirmed at an earlier stage, has not been examined so far.
The purpose of this study is to assess whether the duration of pituitary downregulation with GnRH agonists, prior to initiation of ovarian stimulation with gonadotropins, has any effect on pregnancy rate, in women undergoing IVF.
Eligibility| Ages Eligible for Study: | 19 Years to 38 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- age under 39
- less than 3 previous IVF cycles
- BMI 18-29
- normal ultrasound of internal genital organs
Exclusion Criteria:
- polycystic ovarian syndrome
- endometriosis
Contacts and Locations| Contact: Efstratios Kolibianakis, MD PhD | 00306937096078 | stratis.kolibianakis@irg.gr |
| Contact: Lydia Kalogeropoulou, MD | 0030 6974640068 | lyd_kal@hotmail.com |
| Greece | |
| Unit of Human Reproduction, 1st Department of Obst & Gyn, Aristotle University of Thessaloniki, Papageorgiou Hospital, Greece | Recruiting |
| Thessaloniki, Greece | |
| Contact: Efstratios M Kolibianakis, MD PhD 0030 6937 096 078 stratis.kolibianakis@irg.gr | |
| Principal Investigator: Lydia Kalogeropoulou, MD | |
| Principal Investigator: | Basil C Tarlatzis, MD PhD | Unit of Human Reproduction, 1st Department of Obst & Gyn, Aristotle University of Thessaloniki, Papageorgiou Hospital, Greece |
More Information
Publications:
| ClinicalTrials.gov Identifier: | NCT00436319 History of Changes |
| Other Study ID Numbers: | UHR-2 |
| Study First Received: | February 16, 2007 |
| Last Updated: | February 16, 2007 |
| Health Authority: | Greece: Ministry of Health and Welfare |
Keywords provided by Aristotle University Of Thessaloniki:
|
Infertility, downregulation, stimulation, agonists, long |
Additional relevant MeSH terms:
|
Infertility Genital Diseases, Male Genital Diseases, Female Deslorelin |
Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Pharmacologic Actions |
ClinicalTrials.gov processed this record on June 17, 2013